We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+2.31%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.71B
AUM Growth
+$121M
Cap. Flow
+$218M
Cap. Flow %
5.87%
Top 10 Hldgs %
63.73%
Holding
72
New
5
Increased
8
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$120M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$47.8M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$38.2M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.6M
5
ROIV icon
Roivant Sciences
ROIV
+$31M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$67.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$10.1M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.73M
4
RLAY icon
Relay Therapeutics
RLAY
+$8.12M
5
ITOS
iTeos Therapeutics
ITOS
+$7.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
51
DELISTED
Cidara Therapeutics
CDTX
$6.46M 0.17%
343,056
– –
PVLA
52
Palvella Therapeutics
PVLA
$2.04B
$6.14M 0.17%
257,623
– –
ELDN icon
53
Eledon Pharmaceuticals
ELDN
$257M
$5.93M 0.16%
4,326,710
– –
NCEL
54
NewcelX Ltd
NCEL
$18.1M
$3.97M 0.11%
14,368
– –
DCTH icon
55
Delcath Systems
DCTH
$410M
$3.95M 0.11%
976,149
-202,638
-17% -$950K
KRON
56
DELISTED
Kronos Bio
KRON
$3.78M 0.1%
2,905,043
+91,558
+3% +$148K
VIRX
57
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.76M 0.1%
3,614,662
– –
MTEM
58
DELISTED
Molecular Templates, Inc.
MTEM
$3.36M 0.09%
532,038
+198,934
+60% +$1.58M
RAIN
59
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$3.04M 0.08%
3,526,729
– –
UNCY icon
60
Unicycive Therapeutics
UNCY
$138M
$2.94M 0.08%
+341,356
New +$3.2M
IVA
61
Inventiva
IVA
$1.03B
$2.88M 0.08%
686,040
– –
CRVS icon
62
Corvus Pharmaceuticals
CRVS
$1.09B
$2M 0.05%
1,370,947
– –
FBRX icon
63
Forte Biosciences
FBRX
$1.57B
$1.97M 0.05%
+119,284
New +$2.64M
ASLN
64
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.94M 0.05%
131,250
– –
MOLN
65
Molecular Partners
MOLN
$1.77M 0.05%
443,221
– –
IMUX icon
66
Immunic
IMUX
$190M
$1.69M 0.05%
114,943
– –
ELEV
67
DELISTED
Elevation Oncology
ELEV
$1.53M 0.04%
2,312,200
– –
RZLT icon
68
Rezolute
RZLT
$449M
$252K 0.01%
190,815
– –
NEUP
69
Neuphoria Therapeutics
NEUP
$21M
$128K ﹤0.01%
3,948
-2,800
-41% -$60.4K
GLMD icon
70
Galmed Pharmaceuticals
GLMD
$4.96M
– –
-7,488
Closed -$261K
ARAV
71
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-4,784,214
Closed -$6.03M
INFI
72
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-6,353,645
Closed -$1.34M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2023 Portfolio in Review

As of Q3 2023, BVF Inc held 72 positions worth $3.71B, up 3.4% from $3.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BVF Inc deployed $218M of net new capital in Q3 2023, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 4,370,024 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $67.5M trimmed.

  • BVF Inc's largest Q3 2023 buy was Mirum Pharmaceuticals: 4,370,024 shares worth $138M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2023, an estimated $47.8M increase.
  • BVF Inc's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $67.5M.
  • BVF Inc fully exited Aravive, Inc. Common Stock in Q3 2023, selling an estimated $6.03M.
  • BVF Inc's ten largest holdings make up 64% of its $3.71B portfolio in Q3 2023.
  • BVF Inc opened 5 new positions and closed 3 in Q3 2023.
  • BVF Inc's portfolio value rose 3.4% quarter-over-quarter to $3.71B.

Based on BVF Inc's 13F filing for Q3 2023, filed 14 Nov 2023.